[Skip to Content]
[Skip to Content Landing]

June 2019 - April 2015

Decade

Year

Issue

July 2015, Vol 1, No. 4, Pages 409-550

Original Investigation

Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials

Abstract Full Text
open access
JAMA Oncol. 2015;1(4):433-440. doi:10.1001/jamaoncol.2015.1184

This pooled analysis reports that nivolumab has similar efficacy and safety outcomes in patients with tumors with wild-type or mutant BRAF kinase, regardless of prior BRAF inhibitor or ipilimumab treatment.

A Clinical Prediction Model to Assess Risk for Chemotherapy-Related Hospitalization in Patients Initiating Palliative Chemotherapy

Abstract Full Text
free access
JAMA Oncol. 2015;1(4):441-447. doi:10.1001/jamaoncol.2015.0828

This case-control study finds that in patients initiating palliative chemotherapy for cancer, readily available clinical data can predict patient-specific risk of chemotherapy-related hospitalization.

Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial

Abstract Full Text
free access
JAMA Oncol. 2015;1(4):448-455. doi:10.1001/jamaoncol.2015.0830

This report of NeoALTTO trial data found that the presence of tumor-infiltrating lymphocytes at diagnosis is an independent, positive, prognostic marker in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer treated with neoadjuvant anti-HER2 agents and chemotherapy.

Stereotactic Radiosurgery With or Without Whole-Brain Radiotherapy for Brain Metastases: Secondary Analysis of the JROSG 99-1 Randomized Clinical Trial

Abstract Full Text
free access
JAMA Oncol. 2015;1(4):457-464. doi:10.1001/jamaoncol.2015.1145

In a secondary analysis of a phase 3 randomized clinical trial, Aoyama and colleagues investigated the feasibility of stereotactic radiosurgery alone for patients with brain metastases from non–small-cell lung cancer exhibiting different prognoses, finding that whole-brain radiotherapy for patients with a favorable prognosis should be still be considered.

Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response

Abstract Full Text
free access
JAMA Oncol. 2015;1(4):466-474. doi:10.1001/jamaoncol.2015.1313

This whole-exome sequencing study found that the majority of advanced, treatment-resistant tumors across tumor types harbor biologically informative genetic alterations.

Correlation of Smoking-Associated DNA Methylation Changes in Buccal Cells With DNA Methylation Changes in Epithelial Cancer

Abstract Full Text
free access
JAMA Oncol. 2015;1(4):476-485. doi:10.1001/jamaoncol.2015.1053

The data from this study suggest that buccal cells are likely a more appropriate source of tissue than blood to conduct epigenome-wide association studies for smoking-related epithelial cancers.

Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma

Abstract Full Text
free access
JAMA Oncol. 2015;1(4):486-494. doi:10.1001/jamaoncol.2015.1432

This observational study found that ADAMTS mutations may contribute to outcomes in ovarian cancer cases without BRCA1 or BRCA2 mutations and may have important clinical implications.

Statin Use at the Time of Initiation of Androgen Deprivation Therapy and Time to Progression in Patients With Hormone-Sensitive Prostate Cancer

Abstract Full Text
free access
JAMA Oncol. 2015;1(4):495-504. doi:10.1001/jamaoncol.2015.0829

This retrospective analysis of patients with hormone-sensitive prostate cancer found that statin use at the time of initiation of androgen deprivation therapy was associated with a significantly longer time to progression.

Research Letter

Five Years of Cancer Drug Approvals: Innovation, Efficacy, and Costs

Abstract Full Text
free access
JAMA Oncol. 2015;1(4):539-540. doi:10.1001/jamaoncol.2015.0373
Special Communication

The Global Burden of Cancer 2013

Abstract Full Text
free access has multimedia has audio
JAMA Oncol. 2015;1(4):505-527. doi:10.1001/jamaoncol.2015.0735

Using Global Burden of Disease (GBD) 2013 methodology, the GBD Cancer Collaboration investigators estimate mortality, incidence, years lived with disability, years of life lost, and disability-adjusted life years for 28 cancers in 188 countries by sex from 1990 to 2013.

Review

Changing Treatment Paradigms in Metastatic Breast Cancer: Lessons Learned

Abstract Full Text
free access
JAMA Oncol. 2015;1(4):528-534. doi:10.1001/jamaoncol.2015.1198

This narrative review summarizes recent advances in understanding tumor biology and using targeted therapies for patients with metastatic breast cancer.

JAMA Oncology Clinical Challenge

A Red and Swollen Eyelid

Abstract Full Text
free access
JAMA Oncol. 2015;1(4):537-538. doi:10.1001/jamaoncol.2015.0461
Viewpoint

How Imaging Biomarkers Can Inform Clinical Trials and Clinical Practice in the Era of Targeted Cancer Therapy

Abstract Full Text
free access
JAMA Oncol. 2015;1(4):421-422. doi:10.1001/jamaoncol.2015.0667

As tumors are increasingly treated based on their specific molecular profile, imaging biomarkers should become an essential diagnostic tool for selecting appropriate therapies and assessing their response to treatment.

Advancing a Quality-of-Life Agenda in Cancer Advocacy: Beyond the War Metaphor

Abstract Full Text
free access
JAMA Oncol. 2015;1(4):423-424. doi:10.1001/jamaoncol.2015.0925

This Viewpoint advocates moving beyond the “War on Cancer” metaphor and proposes priorities in clinical practice, messaging, and research to help guide a successful quality-of-life agenda for patients with cancer and cancer survivors.

From the JAMA Network

Cabozantinib—Getting Under the Skin of Cutaneous Toxicity

Abstract Full Text
free access
JAMA Oncol. 2015;1(4):535-536. doi:10.1001/jamaoncol.2015.0702
Editorial

Novel Methods for Measuring Global Cancer Burden: Implications for Global Cancer Control

Abstract Full Text
free access
JAMA Oncol. 2015;1(4):425-427. doi:10.1001/jamaoncol.2015.1426

This editorial discusses the importance of using global burden of cancer assessments to provide an actionable framework for policy makers to improve cancer care, particularly in low- and middle-income countries, where health resources are limited and competing health demands are great.

Broad Applicability of Nivolumab in Melanoma Regardless of BRAF Mutation Status

Abstract Full Text
free access
JAMA Oncol. 2015;1(4):427-428. doi:10.1001/jamaoncol.2015.1237

Progress in Understanding What Is Being Statin(ed) in Prostate Cancer

Abstract Full Text
free access
JAMA Oncol. 2015;1(4):428-430. doi:10.1001/jamaoncol.2015.0833

Delivering Patient-Centered Care in the Setting of Advanced Cancer: What Does a Clinical Risk-Prediction Model Have to Do With It?

Abstract Full Text
free access
JAMA Oncol. 2015;1(4):430-432. doi:10.1001/jamaoncol.2015.0832

A Call for Viewpoints

Abstract Full Text
free access
JAMA Oncol. 2015;1(4):432. doi:10.1001/jamaoncol.2015.1238
Invited Commentary

The Dual Role of Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2–Positive Primary Breast Cancer: Two Sides of the Same Coin?

Abstract Full Text
free access
JAMA Oncol. 2015;1(4):455-456. doi:10.1001/jamaoncol.2015.0851

The Changing Landscape of Whole-Brain Radiation Therapy

Abstract Full Text
free access
JAMA Oncol. 2015;1(4):464-465. doi:10.1001/jamaoncol.2015.1144

Genomic Profiling: Building a Continuum From Knowledge to Care

Abstract Full Text
free access
JAMA Oncol. 2015;1(4):474-475. doi:10.1001/jamaoncol.2015.1333
JAMA Oncology Patient Page

Neoadjuvant Therapy

Abstract Full Text
free access
JAMA Oncol. 2015;1(4):550. doi:10.1001/jamaoncol.2015.1241

Neoadjuvant therapy is explained as cancer treatment given before the main treatment to increase the main treatment’s chances of success

Comment & Response

Genomic Profiling of Cancers of Unknown Primary Site: The Next Steps

Abstract Full Text
free access
JAMA Oncol. 2015;1(4):541. doi:10.1001/jamaoncol.2015.0936

Genomic Profiling of Cancers of Unknown Primary Site: The Next Steps

Abstract Full Text
free access
JAMA Oncol. 2015;1(4):541-542. doi:10.1001/jamaoncol.2015.0939

Genomic Profiling of Cancers of Unknown Primary Site: The Next Steps

Abstract Full Text
free access
JAMA Oncol. 2015;1(4):542. doi:10.1001/jamaoncol.2015.0942

Genomic Profiling of Cancers of Unknown Primary Site—Reply

Abstract Full Text
free access
JAMA Oncol. 2015;1(4):542-543. doi:10.1001/jamaoncol.2015.0945

The Demanding Patient Revisited

Abstract Full Text
free access
JAMA Oncol. 2015;1(4):543. doi:10.1001/jamaoncol.2015.1105

The Demanding Patient Revisited

Abstract Full Text
free access
JAMA Oncol. 2015;1(4):543-544. doi:10.1001/jamaoncol.2015.1108

The Demanding Patient Revisited—Reply

Abstract Full Text
free access
JAMA Oncol. 2015;1(4):544. doi:10.1001/jamaoncol.2015.1111
Correction

Error in Table Text

Abstract Full Text
free access
JAMA Oncol. 2015;1(4):544. doi:10.1001/jamaoncol.2015.1424

Error in Figure

Abstract Full Text
free access
JAMA Oncol. 2015;1(4):544. doi:10.1001/jamaoncol.2015.1805

Error in Abstract

Abstract Full Text
free access
JAMA Oncol. 2015;1(4):544. doi:10.1001/jamaoncol.2015.2066

Incorrect Units in Methods

Abstract Full Text
free access
JAMA Oncol. 2015;1(4):544. doi:10.1001/jamaoncol.2015.2075
JAMA Oncology Masthead

JAMA Oncology

Abstract Full Text
free access
JAMA Oncol. 2015;1(4):411. doi:10.1001/jamaoncol.2014.247
In This Issue of JAMA Oncology

Highlights

Abstract Full Text
free access
JAMA Oncol. 2015;1(4):409. doi:10.1001/jamaoncol.2015.0725
×